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relaxinnitric oxide synthasesG protein Researchers involved in the study of relaxin have wel-
comed the article by Hsu et al. [1], who eventually identi-
fied the receptors for this hormone. In the past, using
labeled relaxin, specific binding sites have been found in
several target organs and tissues for this hormone [2–4],
but the exact molecular and functional nature of the relax-
in receptor remained elusive. Relaxin is structurally simi-
lar to insulin and insulin-like growth factors (IGFs) [5],
hence it seemed logical to assume that its putative recep-
tor should belong to the insulin family of receptors, which
are membrane-associated tyrosine kinases. Nonetheless,
studies in this direction have been unfruitful and even
misleading, as experienced by Dr Ivell and his team. In a
recent study they were at a very short step from a crucial
discovery, because they found that the relaxin-induced
cAMP accumulation in target cells in in vitro culture was
prevented by a pharmacologic inhibitor of G protein acti-
vation [6]. However, their attention being focused on ty-
rosine phosphorylation, they did not go deep into this
finding. Using a completely different approach, Hsu and
coworkers noticed that knock-out mice for the relaxin-like
factor/Insl3 (also known as Leydig cell relaxin) had an ab-
normal testis descent phenotype [7,8] which was similar
to that of mice with a disruption of a G protein-coupled
receptor (GPCR) gene [9]. On these grounds, they
screened the human and mouse genome for orphan
GPCRs and they could smartly demonstrate that relaxin is
a cognate ligand for two leucine-rich repeat-containing
GPCRs, LGR7 and LGR8, acting through Gs proteins. Acti-
vation of adenylate cyclase by Gs proteins can explain why
relaxin induces an elevation of cAMP in target cells and
tissues [5]. In particular, in the same article cited above
[1], Hsu and coworkers demonstrated that LGR7 and
LGR8 are capable of mediating the action of relaxin
through a cAMP-dependent pathway distinct from that of
insulin and IGF family ligands.
In recent years, our own studies and those of other inves-
tigators have provided increasing evidence that relaxin can
also act on several of its targets by increasing the expres-
sion and/or activity of nitric oxide synthase (NOS) isoen-
zymes, thereby promoting the generation of nitric oxide
(NO) [10–16]. Time is ripe for investigating how the new-
ly discovered relaxin GPCRs may account for this. Based
on the current literature, there are multiple pathways by
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Figure 1
Putative interactions between relaxin receptor sign-
aling and intrinsic NO pathway. AC: adenylate cyclase 
Akt: protein kinase B Gs: Gs proteins IκB inhibitor subunit of 
nuclear factor kappa-B LGR7-8: leucine-rich repeat-contain-
ing G protein-coupled receptors 7 and 8 NF-κB nuclear fac-
tor kappa-B NO: nitric oxide NOS II: inducible NO synthase 
NOS III: constitutive NO synthase PI3-K: phosphoinositide 3-
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which GPCRs can stimulate NO biosynthesis. In endothe-
lial cells, the best-described agonists for the constitutive
NOS III isoform, acetylcholine and bradykinin, activate
specific membrane-associated GPCRs [17,18]. Similar ef-
fects are exerted by surface estrogen receptors [19]. It has
been reported that NOS III can be also activated by direct
stimulation of GPCRs with sphingosine 1-phosphate
[20]. The classical signaling pathway appears to involve G
protein βγ subunits that, by means of phosphoinositide 3-
kinase (PI3-K), switch on protein kinase B (Akt), which in
turn activates eNOS by phosphorylation at Ser-1179 [20].
Another mechanism, which may either coexist in the same
cell or be alternatively operating in different cell types,
could involve cAMP and the inducible NOS II isoform. In
rat vascular smooth muscle cells, GPCR-activated ade-
nylate cyclase and the consequent rise in cAMP upregu-
lates protein kinase A (PKA) activity [21]. In turn, PKA is
able to phosphorilate and inactivate IkB-α, the inhibitor
subunit of the transcription factor NF-κB, thus allowing
NF-κB to translocate into the nucleus and to promote the
expression of NOS II [22]. This latter mechanism may be
operating in some relaxin targets, in which induction of
NOS II expression and/or high-output, sustained NO gen-
eration have been observed [11,12,15,16], NOS II being
far more active than NOS III [23]. As summarized in Fig-
ure 1, at present there are some clues but no definitive
data about the molecular mechanisms by which relaxin,
by binding to its GPCRs, may induce the activation of the
NO pathway in its targets. Hopefully, future research
would clarify this point.
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